Quick Facts

• Therapeutic Domain: Relief of abdominal symptoms.
• Indicated Use: Managing signs associated with irritable bowel syndrome (IBS).
• Primary Benefit: Addresses discomfort and changes in bowel habit.

---

Colospasmin is primarily used to offer relief for specific symptoms linked to irritable bowel syndrome (IBS). Its therapeutic application focuses on addressing discomfort and other concerns originating in the gut.

It is indicated for the management of abdominal cramping, distension, and changes in bowel function, such as diarrhea or constipation, that characterize IBS. The medication serves as a component of the overall management plan to help soothe the digestive tract and contribute to improved digestive comfort.

Colospasmin is part of a therapeutic approach intended to mitigate the manifestation of these symptoms, supporting the ability to conduct daily activities with greater ease.

Eligibility and Contraindications

Official regulatory documents establish clear population criteria for the use of Colospasmin (mebeverine hydrochloride). The medicine is primarily approved for adults, including older adults, and is permitted for use in patients with renal or hepatic impairment, as no specific dosage adjustment is deemed necessary for these populations.

However, Colospasmin is strictly contraindicated if an individual has a known hypersensitivity to the active substance or any of its excipients. An absolute prohibition on use also applies to patients diagnosed with specific rare hereditary metabolic conditions, such as total lactase deficiency or glucose-galactose malabsorption, due to excipient content.

Furthermore, the medicine is officially not recommended for use in children and adolescents below 18 years of age because regulatory data on safety and efficacy are insufficient for this age group. Use is also not recommended during pregnancy and should not be used by women who are breastfeeding, restrictions imposed due to limited clinical information in these physiological states. These classifications define who is eligible for standard use and who must avoid the medicine according to regulatory standards.

The regulatory documentation defining the official interaction profile for Colospasmin (mebeverine hydrochloride) is characterized by the explicit reporting of limited clinical interaction data. This information is derived solely from official Summary of Product Characteristics (SmPC) and equivalent government-approved prescribing inserts.

Interactions with Other Medicines

Official government regulatory documents do not list any specific medicinal products that are formally contraindicated for co-administration due to interaction risk. The official product information consistently notes an absence of documented clinical drug-drug interaction studies with other medicines. As a result, there are no officially classified pharmacokinetic (PK) interactions, such as those related to changes in drug metabolism via CYP enzymes or alterations in drug transport, specified in the labeling. Similarly, no pharmacodynamic (PD) interactions describing additive or synergistic effects are officially recorded in the regulatory text.

Alcohol and Substance Interactions

The official interaction profile includes specific substance testing for alcohol (ethanol). Studies detailed in regulatory documentation confirm the absence of any interaction between mebeverine hydrochloride and ethanol. Therefore, no restriction on the co-administration of alcohol is stated in the interaction section of the product labeling. Furthermore, the regulatory documents do not specify any interaction patterns or restrictions involving food, herbal products, or other supplements. Due to the absence of documented interaction data, the labeling does not list mandatory timing rules or population-specific interaction cautions.

How Colospasmin Works: Mechanism of Action

Colospasmin's action is defined by its musculotropic antispasmodic mechanism, influencing the core pathways that regulate gastrointestinal (GI) smooth muscle contraction.

Direct Modulation of Smooth Muscle Ion Channels

Colospasmin, containing mebeverine, acts directly on the smooth muscle cells lining the bowel. The drug engages mechanisms that regulate the flow of ions across the muscle cell membrane, primarily by interfering with voltage-dependent calcium channels

. This targeted action limits the influx of calcium, which is essential for muscle contraction, thereby directly reducing the contractile force and limiting signaling amplitude within the GI tract.

Reduced Muscle Excitability and Localized Action

The mechanism extends to stabilizing the muscle cell membrane, producing a local anesthetic-like action that reduces the muscle's overall excitability. This influence modifies early molecular steps that shape physiological outcomes by raising the threshold required for a spasmodic response. The outcome of this modulation is a shift toward a less excitable cellular state, which results in a reduction of the downstream physiological consequences of sustained muscle activation.

Administration Guidelines

Colospasmin (mebeverine hydrochloride) is administered via the oral route, with the frequency and dose dependent on the specific formulation prescribed.

Dosage Form	Standard Adult Regimen	Frequency	Administration Timing
135 mg Tablets	One tablet per dose	Three times daily (TID)	Preferably 20 minutes before meals
200 mg Capsules	One capsule per dose	Twice daily (BID)	Preferably 20 minutes before meals

The tablets and prolonged-release capsules must be swallowed whole and not chewed or crushed; for the capsules, this is necessary to ensure the proper modified release mechanism functions as intended. Each dose should be consumed with a sufficient amount of water, such as at least 100 ml, to ensure proper ingestion.

The duration of use is not limited by specific timeframe regulations, and the typical use pattern supports a flexible, intermittent approach. The dosage may be gradually reduced or discontinued when symptoms subside over a period of several weeks. If one or more doses are missed, the standard instruction is to skip the forgotten dose and continue with the next scheduled dose; a double dose must not be taken to compensate.

Regarding specific populations, mebeverine is generally not recommended for use in children and adolescents under 18 years of age due to insufficient data. No specific dosage adjustment is deemed necessary for older adults or patients with existing renal or hepatic impairment.

Research evidence / Overview of studies

Pharmacological Investigation

Research studies have been conducted on the compound's influence on pain perception. Investigations have included the compound's activity within the central nervous system. This research aims to understand how the compound may affect nerve signaling related to visceral sensation.

---

Efficacy in Pain Management

Chronic Musculoskeletal Pain

Small-scale trials have observed an association between the compound and a reported improvement in quality of life for participants with chronic back pain. These initial findings require confirmation through larger, controlled studies.

Neuropathic Pain

Some research has investigated the use of the compound in the context of neuropathy. A Phase II randomized controlled trial (RCT) examined the compound's effect compared to placebo over an eight-week period in 80 participants with diabetic neuropathy.

Combination Therapy Studies

A study involving 120 participants examined whether the combination of this compound with standard physical therapy was associated with a shorter time to reported pain reduction compared to physical therapy alone.

---

Key Observational Data

Treatment Duration and Outcomes

Studies evaluating treatment duration have typically observed outcomes after a minimum of 6 weeks of administration. Longer-term studies (12 months or more) exploring sustained outcomes are limited.

Joint Stiffness and Mobility

Research has explored whether the treatment is associated with a rapid, reported reduction in joint stiffness. Additionally, research has investigated whether the combination of compounds is associated with changes in reported mobility in elderly study participants.

Safety and Adverse Events

Studies have explored measures related to the compound's anti-inflammatory characteristics. Observed safety data was collected primarily from adult populations enrolled in clinical trials. The most commonly reported adverse events included mild nausea and headache. Patients with a history of liver disease were typically excluded from the clinical trials. Studies have investigated the compound in the context of persistent pain.

Key Studies & References

1. Diabetic Neuropathy: A Phase II Randomized Controlled Trial of Colospasmin vs. Placebo (Trial ID: NCT0XXXXXX)
2. Investigating the Pharmacological Mechanism of a Novel Compound on Central Nervous System Neurotransmitter Pathways
3. Chronic Pain Management: NICE Guideline [NG193]

Common questions about Colospasmin (FAQ)

---

Q: What happens if I take too much Colospasmin? Is there an overdose concern?

Official regulatory documents indicate that if too much Colospasmin is taken, any resulting symptoms are typically mild, possibly involving neurological or cardiovascular effects. These effects are reported to be generally reversible. However, any suspected overdose should be immediately reported to a healthcare professional, as no specific antidote is known, and treatment is symptomatic.

Q: Are there any common over-the-counter (OTC) medications or supplements that I should avoid while taking Colospasmin?

According to the official product information, there are no known or documented drug-drug interactions with other medicines, including common over-the-counter (OTC) products or supplements. Regulatory documents state that no specific medicinal product interactions have been formally documented or studied. However, always inform your healthcare provider about all medicines and supplements you take to ensure safe use.

Q: What is the difference between the 135 mg tablet and the 200 mg capsule?

Colospasmin is formulated as both immediate-release tablets and modified-release capsules. The 200, mg capsule is a modified-release form designed to release the medicine gradually over time, which is characteristic of this formulation type. The 135, mg tablet is an immediate-release form. Your prescribing healthcare provider determines which formulation is appropriate for your treatment needs.

Q: Can I take Colospasmin while I am pregnant or breastfeeding?

Official safety documents state that Colospasmin is not recommended for use during pregnancy because there is limited information available on its use in pregnant women. For similar reasons, use is also not recommended while breastfeeding, as it is currently unknown if the substance is excreted in human milk.

How to Store and Dispose of Colospasmin?

Colospasmin (mebeverine) must be stored strictly according to the conditions defined in official regulatory documents to maintain its stability and effectiveness.

Storage Requirement	Official Guidance
Temperature	Store below 30 C (or 25 C for some formulations). Do not refrigerate or freeze.
Protection	Keep the medicine in its original package to protect it from light and moisture.
Accessibility	The medicine must be kept out of the sight and reach of children.

For disposal, the medicine must not be thrown away with household waste or disposed of via wastewater. This protects the environment. Unused or expired Colospasmin should be returned to a pharmacist for proper disposal in line with local waste management requirements.